I missed a pill femoston 2 10 what to do. Femoston when planning pregnancy. Femoston, instructions for use. Interaction with other drugs

Pharmacodynamics. combined estrogen-gestagenic drug.
Estradiol
Estradiol is chemically and biologically identical to the natural human sex hormone estradiol. Among ovarian hormones, it has the highest activity. Estradiol causes cyclic changes in the uterus, cervix and vagina and maintains the tone and elasticity of the urinary tract. Estradiol also plays an important role in maintaining bone tissue, preventing osteoporosis and fractures. Oral intake of estrogens has a positive effect on lipid metabolism, has a beneficial effect on the autonomic nervous system and an indirect positive effect on the psycho-emotional sphere.
Dydrogesterone
Dydrogesterone is an orally effective progestogen that is comparable to parenteral progesterone. In the context of hormone replacement therapy, dydrogesterone contributes to the complete secretory transformation of the uterine endometrium, thus preventing the risk of developing estrogen-induced endometrial hyperplasia and/or carcinoma, without excluding androgenic side effects. Due to the fact that estrogens stimulate the growth of the endometrium, estrogen monotherapy increases the risk of endometrial hyperplasia and cancer. The use of progestogen in therapy reduces the estrogen-induced risk of endometrial hyperplasia in women with preserved uterus.
Clinical Study Data
Reducing symptoms of estrogen deficiency and improving the bleeding profile
A decrease in the severity of menopausal symptoms was achieved during the first weeks of treatment. Regular menstrual-like reactions (average duration 5 days) with the use of the drug Femoston, which contains 2 mg of estradiol and 10 mg of dydrogesterone, were observed in approximately 90% of women. Menstruation usually began on the day of the last tablet of the progestogen phase. Breakthrough uterine bleeding and/or spotting has been reported in approximately 10% of women. During the first year of therapy, amenorrhea (no bleeding or spotting) was observed in 5-15% of women per cycle.
Regular menstrual-like reactions with the use of the drug Femoston, which contains 1 mg of estradiol and 10 mg of dydrogesterone, were observed in 75-80% of women. The day of the onset of menstruation, its duration, as well as the number of women with periodic menstrual-like reactions were the same as when using Femoston, which contains 2 mg of estradiol and 10 mg of dydrogesterone, but there were more women with no menstruation (10-25% per 1 cycle).
Prevention of osteoporosis
Estrogen deficiency at menopause is associated with increased bone turnover and decreased bone mass. The effect of estrogens on bone mineral density is dose dependent. The protective effect of estrogens is only valid during their use. After discontinuation of hormone replacement therapy (HRT), the rate of bone loss is the same as in women who did not receive this therapy.
Data from the WHI (Women Health Initiative) study and the purpose of the analysis of studies suggest that current HRT, predominantly in healthy women, as monotherapy or in combination with a progestogen, reduces the risk of fractures of the femur, vertebrae and other types of fractures that occur due to osteoporosis. HRT may also prevent fractures in women with low bone density and/or diagnosed osteoporosis, but data are limited.
After two years of treatment with Femoston, which contains 2 mg of estradiol and 10 mg of dydrogesterone, bone mineral density (BMD) in the lumbar spine increased by 6.7% ± 3.9%. During treatment, BMD in the lumbar spine increased or remained unchanged in 94.4% of women. In women who took the drug Femoston, which contains 1 mg of estradiol and 10 mg of dydrogesterone, BMD in the lumbar spine increased by 5.2% + 3.8%. BMD in the lumbar spine increased or remained unchanged during treatment in 93.0% of women.
Femoston will affect BMD of the femur. After two years of therapy with 1 mg estradiol, BMD of the femoral neck increased by 2.7% ± 4.2%, by 3.5% ± 5.0% in the trochanteric zone and by 2.7% ± 6.7% in Ward's triangle . After two years of treatment with estradiol at a dose of 2 mg, these figures were 2.6% ± 5.0%; 4.6% ± 5.0% and 4.1% ± 7.4%, respectively. BMD in three areas of the femur increased or remained unchanged after estradiol therapy at a dose of 1 and 2 mg in 67-78% and 71-88% of women, respectively.
Pharmacokinetics.
Estradiol
After oral administration, micronized estradiol is rapidly absorbed and extensively metabolized. The main unconjugated and conjugated metabolites are estrone and estrone sulfate. These metabolites have estrogenic activity both directly and after their conversion to estradiol. Estrone sulfate may be susceptible to enterohepatic metabolism. Major compounds found in urine , are the glucuronides of estrone and estradiol. Estrogens pass into breast milk.
Dydrogesterone
After oral administration, approximately 63% of dydrogesterone is excreted in the urine. The drug is completely eliminated after 72 hours. In the body, dydrogesterone is completely metabolized. The main metabolite of dydrogesterone is 20-α-dihydrodydrogesterone (DHD), which is found predominantly in the urine as a glucuronic acid conjugate. A common feature of all metabolites is that they retain the 4,6-dien-3-one configuration and the absence of a hydroxylation reaction under the action of 17α-hydroxylase. This explains the absence of estrogenic and androgenic effects in dydrogesterone. After the introduction of dydrogesterone inside, the concentration of DHD in the blood plasma significantly exceeds the level of the parent substance. Dydrogesterone is rapidly absorbed. The time to reach the maximum concentration for dydrogesterone and DHD varies within 0.5-2.5 hours. The half-lives for dydrogesterone and DHD are 5-7 and 14-17 hours, respectively. Unlike progesterone, dydrogesterone is not excreted in the urine in the form of pregnandiol. Thus, it remains possible to analyze the formation of endogenous progesterone based on the measurement of excretion of pregnandiol.

Indications for use of the drug Femoston

Hormone replacement therapy for disorders caused by estrogen deficiency in postmenopausal women.
Prevention of osteoporosis in postmenopausal women at high risk of fractures in case of intolerance or contraindications to the use of other drugs for the prevention of osteoporosis.

The use of the drug Femoston

To start and continue treatment of postmenopausal symptoms, it is necessary to prescribe the minimum effective dose for the minimum period of time.
Femoston in the first 14 days of a 28-day cycle, take 1 tablet daily, containing 1 or 2 mg of estradiol, and in the remaining 14 days, take 1 tablet daily, containing 1 mg of estradiol and 10 mg of dydrogesterone or 2 mg of estradiol and 10 mg of dydrogesterone. After the end of the 28-day cycle, a new cycle should begin. Treatment must be continuous. Tablets should be taken in the order indicated on the package.
Treatment of postmenopausal symptoms
Usually they start with Femoston, containing 1 mg of estradiol and 10 mg of dydrogesterone. Depending on the clinical effect, the further dose is selected individually. If the severity of symptoms associated with estrogen deficiency does not decrease, the dose can be increased by prescribing a drug that contains 2 mg of estradiol and 10 mg of dydrogesterone.
Prevention of osteoporosis

Femoston Conti 1 tablet 1 time per day, daily, without interruption, regardless of food intake.
Prevention of osteoporosis
With hormone replacement therapy, it is necessary to take into account the individual tolerability of treatment and that the expected effect of the drug on bone tissue is dose-dependent.

Contraindications to the use of the drug Femoston

Hypersensitivity to the components of the drug; diagnosed or suspected breast cancer, endometrial carcinoma and other hormone-dependent tumors diagnosed or suspected; vaginal bleeding of unknown etiology; untreated endometrial hyperplasia; acute deep vein thrombosis, pulmonary embolism or idiopathic venous thromboembolism in history; arterial thromboembolism, including recently transferred (for example, angina pectoris, myocardial infarction); acute and chronic liver diseases, as well as their presence in history in the absence of normalization of functional state indicators; porphyria; established or suspected pregnancy.

Side effects of Femoston

Often (1-10%): headache, migraine, nausea, abdominal pain, flatulence, leg cramps, breast pain, breakthrough bleeding, spotting, pelvic pain, asthenia, weight loss or gain.
Uncommon (≤1%): vaginal candidiasis, increase in the size of uterine fibroids, depression, changes in libido, irritability, dizziness, venous thromboembolism, gallbladder disease, allergic skin reactions, rash, urticaria, itching, back pain, changes in cervical erosion and the amount of cervical secretion, dysmenorrhea, peripheral swelling.
Rare (≤0.1%): intolerance to contact lenses, an increase in the curvature of the cornea, abnormal liver function, which may be accompanied by asthenia, malaise, jaundice and abdominal pain, breast enlargement, a syndrome similar to premenstrual.
Very rare (≤0.01%): hemolytic anemia, hypersensitivity reactions, chorea, myocardial infarction, stroke, vomiting, chloasma and melasma, which may persist after discontinuation of the drug, erythema multiforme, erythema nodosum, vascular purpura, angioedema, deterioration in porphyria.
Mammary cancer
According to the results of a large number of epidemiological studies and one randomized, placebo-controlled study (Women Health Initiative - WHI), the overall risk of breast cancer increases with increasing duration of hormone replacement therapy (HRT) in women who receive this treatment, or who are on HRT carried out in the recent past.
For estrogen-only HRT, the relative risk (RR) scores from a reanalysis of data from 51 epidemiological studies (in which estrogen-only HRT was administered in more than 80% of all HRT cases) and the MWS (Million Women Study) epidemiological study are similar at 1.35 (95% confidence interval - CI: 1.21-1.49) and 1.30 (95% CI: 1.21-1.40), respectively.
With regard to combined HRT (estrogen plus progestogen), several epidemiological studies have reported a higher overall risk of breast cancer than with estrogen alone.
The MWS study demonstrated that, compared with patients who never received HRT, the use of combined (progestogen plus estrogen) HRT of different types was associated with a higher risk of breast cancer (RR = 2.00, 95% CI: 1 .88-2.12) than with estrogen alone (RR = 1.30, 95% CI: 1.21-1.40) or tibolone (RR = 1.45; 95% CI: 1.25-1. 68).
In the WHI study, the risk for all patients was 1.24 (95% CI: 1.01-1.54) after 5.6 years of combined (progestogen plus estrogen) HRT (conjugated equine estrogens - CLE and methylprogesterone acetate - MPA) in comparison with placebo.
The absolute risks calculated in the MWS and WHI studies are presented below:
Based on data on the average incidence of breast cancer in developed countries, the MWS found the following: it can be expected that breast cancer will be diagnosed in approximately 32 out of 1000 women aged 50 to 64 who are not receiving HRT;
per 1000 women who have recently received or are receiving HRT, the number of additional cases during the corresponding period will be for those receiving estrogen replacement therapy only
0 to 3 (best estimate = 1.5) over 5 years;
3 to 7 (best estimate = 5) over 10 years;
for those receiving combined (estrogen plus progestogen) HRT
5 to 7 (best estimate = 6) over 5 years;
18 to 20 (best estimate = 19) when used for 10 years.
The WHI study found that after 5.6 years of follow-up in women aged 50 to 79 years on combined estrogen-progestagen HRT (CLE and MPA), an additional 8 cases of invasive breast cancer per 10,000 woman-years will be diagnosed.
According to the statistics of the study, it was found that:
for every 1000 women in the placebo group, approximately 16 cases of invasive breast cancer would be diagnosed after 5 years;
per 1000 women who received combined estrogen + progestogen HRT (CLE and MPA), the number of additional cases will be from 0 to 9 (best estimate = 4) when used for 5 years.
The number of additional cases of breast cancer in women who use HRT is similar to that in women who started HRT, regardless of their age at the start of use (45 to 65 years).
Other adverse reactions reported in connection with estrogen/progestogen therapy:

• estrogen-dependent neoplasms, both benign and malignant, for example, endometrial cancer, ovarian cancer;
• venous thromboembolism, that is, deep vein thrombosis of the lower extremities or pelvis and pulmonary embolism, is more common among - women who receive HRT than among those who do not receive it;
• arterial thromboembolism;
• an increase in the size of neoplasms caused by a progestogen (for example, meningioma);
• dementia.

endometrial cancer
In women with an intact uterus, the risk of hyperplasia and endometrial cancer increases with increasing duration of estrogen monotherapy. According to epidemiological studies, the best estimate of risk is that women who do not take HRT can be expected to be diagnosed with endometrial cancer in approximately 5 out of 1000 cases at the age of 50 and 65 years. Depending on the duration of treatment and the dose of estrogen, the risk of developing endometrial cancer among those who take only estrogen is 2-12 times greater than those who do not take it. The addition of a progestogen to estrogen monotherapy significantly reduces this increased risk.

Special instructions for the use of the drug Femoston

Hormone replacement therapy should only be started if symptoms are present that adversely affect quality of life. In all cases, a careful risk-benefit analysis should be carried out at least annually, and treatment should only be continued if the benefit outweighs the risk.
Before the appointment of hormone replacement therapy or its resumption, it is necessary to conduct a thorough general and gynecological examination of the patient, to study her individual and family history to identify possible contraindications and risk factors. During the treatment period, it is recommended to conduct regular examinations, the frequency and volume of which are determined individually, with a mandatory examination of the mammary glands and / or mammography, modified if necessary.
Diseases in which it is necessary to monitor the condition of patients: uterine fibroids or endometriosis; a history of thromboembolic disease or the presence of risk factors for thromboembolism (see below); the presence of risk factors for the occurrence of estrogen-dependent tumors, for example, the first degree of hereditary predisposition to breast cancer; AG (arterial hypertension); liver disease (eg liver adenoma); diabetes mellitus with or without vascular complications; cholelithiasis; migraine or (severe) headache; systemic lupus erythematosus; history of endometrial hyperplasia (see below); epilepsy; BA; otosclerosis.
The drug should be discontinued: when contraindications to use are identified, as well as with the development of jaundice or liver dysfunction, a significant increase in blood pressure, the appearance (for the first time) of migraine headache, pregnancy.
hyperplasia of the endometrium. When treated only with estrogen drugs for a long time, the risk of developing hyperplasia and endometrial cancer increases. The addition of progestogen to treatment for at least 12 days of the cycle in women with preserved uterus significantly reduces this risk.
Bleeding. Sometimes in the first months of treatment, breakthrough uterine bleeding or spotting may occur. If they occur during treatment after some time or they are noted after discontinuation of the drug, it is necessary to find out their cause (endometrial biopsy to exclude malignant neoplasms).
Venous thromboembolism. Hormone replacement therapy increases the risk of developing venous thromboembolism (VTE), that is, deep vein thrombosis or pulmonary embolism. The occurrence of this condition is most likely during the first year of treatment. Risk factors for the development of VTE are a history of thromboembolism in the history of the patient or members of her family, severe obesity (body mass index of body weight 30 kg/m2) and systemic lupus erythematosus. In the presence of a history of thromboembolism, as well as with repeated spontaneous abortions, it is necessary to conduct an examination in order to exclude a tendency to thrombosis. Until a thorough assessment of thrombophilic factors has been completed or anticoagulant therapy has been initiated, the use of hormone replacement therapy in such patients should be considered contraindicated. In women taking anticoagulants, a careful risk/benefit analysis of the use of hormone replacement therapy should be carried out.
The risk of thromboembolism increases with prolonged immobilization, significant trauma, or major surgery. As for all patients in the postoperative period, special attention should be paid to preventive measures to prevent thromboembolic complications after surgery. If prolonged immobilization is planned after surgery, namely after operations on the abdominal organs or orthopedic operations on the lower extremities, it is necessary to consider the possibility of temporarily stopping hormone replacement therapy 4-6 weeks before surgery. Treatment cannot be resumed until the woman's motor activity is fully restored.
If VTE develops after the start of therapy, the drug should be discontinued. Patients should be warned to seek immediate medical attention if they develop potential symptoms of thromboembolism (eg, painful leg swelling, sudden chest pain, shortness of breath).
Disease of the coronary arteries of the heart. In randomized controlled trials, no evidence of a positive effect on the cardiovascular system was obtained with continuous combination therapy with conjugated estrogens and MPA. Two large clinical studies WHI and HERS (Heart and Estrogen/Progestin Replacement Study) demonstrated a possible increased risk of developing cardiovascular disease during the first year of treatment and no positive effect in general. For other drugs that are used for HRT, there are only limited data from randomized controlled trials that have studied effects on cardiovascular disease or mortality. Therefore, it is not known whether these results also apply to other HRT preparations.
Stroke. In a large randomized clinical trial (WHI study), as a secondary result, an increase in the risk of ischemic stroke in healthy women during the use of continuous combination therapy with conjugated estrogens and MPA was found. For women who do not receive HRT, it is estimated that the incidence of stroke occurring over a 5-year period will be approximately 3 per 1000 women aged 50-59 and 11 per 1000 women aged 60-69. It is estimated that for women who take conjugated estrogens and MPA for 5 years, the number of additional cases will occur in the range from 0 to 3 (best estimate = 1) per 1000 patients aged 50-59 years and from 1 to 9 (best estimate = 4) per 1000 patients aged 60-69 years. It is not known whether the increased risk of stroke also applies to other drugs for HRT.
Ovarian cancer. Long-term (at least 5-10 years) use of estrogen-only hormone replacement therapy in hysterectomized women has been associated with an increased risk of ovarian cancer. It is not known whether the risk will differ with prolonged use of combined HRT and drugs that contain only estrogens.
Other states. Estrogens can cause fluid retention, and therefore patients with impaired cardiac or renal function should be carefully monitored. The condition of patients with end-stage renal failure requires constant monitoring, since it is possible to increase the level of circulating active ingredients of Femoston.
Women with hypertriglyceridemia should be under constant supervision during hormone replacement therapy, since isolated cases of a significant increase in plasma TG levels have been observed during estrogen treatment, which led to the development of pancreatitis.
Estrogens increase thyroxine-binding globulin, leading to an increase in circulating total thyroid hormone, as measured by protein-bound iodine, thyroxine (by column or radioimmunoassay), or triiodothyronine (by radioimmunoassay). Triiodionine uptake is reduced, indicating elevated levels of thyroxine-binding globulin. The concentrations of free triiodothyronine and thyroxine do not change. Serum levels of other binding proteins—corticosteroid-binding globulin and sex hormone-binding globulin—may be elevated, resulting in elevated circulating corticosteroids and sex hormones, respectively. The concentrations of free or biologically active hormones do not change. Other plasma proteins may increase (angiotensinogen/renin substrate, alpha-I antitrypsin, ceruloplasmin).
There is no strong evidence for improvement in cognitive function. The WHI study found evidence of an increased risk of dementia in women who received continuous combination therapy with estrogen and progesterone after the age of 65 years. It remains unknown whether this also applies to younger postmenopausal women or other hormone replacement drugs.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Experience in the treatment of women over 65 years of age is limited.
Use during pregnancy and lactation.
Femoston is not indicated for use during pregnancy. If pregnancy occurs during treatment with Femoston, the drug should be stopped immediately. Femoston is not recommended for use during lactation.
Children.
Due to insufficient data on the safety and efficacy of Femoston in children under the age of 18, the drug is not recommended for this age group of patients.
The drug Femoston does not affect the ability to drive vehicles and work with machines and mechanisms.

Interactions of the drug Femoston

Metabolism of estrogens may increase with simultaneous use with substances that activate enzymes (cytochrome P450 systems), take part in the metabolism of drugs. These agents include anticonvulsants (eg, phenobarbital, carbamazepine, phenytoin) and antimicrobials (eg, rifampicin, rifabutin, nevirapine, efavirens). Ritonavir and nelvinavir, when used simultaneously with steroid hormones, activate the above enzymes. Herbal preparations, the component of which is St. John's wort (Hypericum perforatum), increase the metabolism of estrogens and progestogens, which can lead to a weakening of their effect and a change in the profile of uterine bleeding.
There is no information on the interaction of dydrogesterone with other drugs.

Femoston overdose, symptoms and treatment

Estradiol and dydrogesterone are substances of low toxicity. Theoretically, in case of an overdose, nausea, vomiting, drowsiness, dizziness are possible. It is unlikely that overdose will require specific symptomatic treatment. This also applies to cases of overdose in children.

Storage conditions of the drug Femoston

At temperatures up to 30 °C.

List of pharmacies where you can buy Femoston:

• Saint Petersburg

After 45 years. However, it can come earlier (35-40 years). Early and standard menopause have the same manifestations: menstrual irregularities, and sometimes the complete absence of menstruation, psycho-emotional disorders in the form of irritability, insomnia, excessive fatigue. With this kind of manifestations, various anticlimacteric agents help to cope. An excellent solution in, including with early menopause, will be the Femoston complex remedy in all its varieties: 1/10, 2/10 and 1⁄5 conti. And with early menopause, Femoston 2/10 gains the most positive feedback. Features of the Femoston line of medicines for all types of menopause are presented below.

Varieties and indications for the use of Femoston

With the onset of menopause, the production of major hormones, in particular estrogens, decreases. HRT comes to the rescue, the essence of which is the artificial introduction of the missing amount of hormones into the body in order to stabilize the hormonal background and relieve the burden on the body. At each stage of menopause, premenopause, menopause and postmenopause, the level of hormones is completely different, as in premature and artificial menopause, so the drugs are also prescribed differently and in different dosages.

1/10

Femoston 1/10 is prescribed in the early stages of menopause, when the hormone deficiency is not so great. The main focus of its action is when the woman's body is still reproductive.

1/5 conti

The dosage of the drug 15 conti is prescribed for women who have longer than usual. If unpleasant manifestations have already been stopped, then 1/5 of the conti becomes excellent, cardiovascular diseases.

2/10

Femoston 2/10 is the most common representative of the line of drugs due to the effective combination of active substances and their dosage. It contains synthetic hormones that fully simulate the action of natural hormones.

Since the psycho-emotional system suffers first of all with the onset of the menopause, the drug eliminates such manifestations as absent-mindedness, sudden mood swings, stress, unreasonable sadness, irritability, apathy, fatigue, insomnia.

Hormonal surges send false signals to the pituitary gland, which is responsible for thermoregulation, as a result of which a woman can be tormented by hot flashes up to 30 times a day, and chills come to replace them. Violation of the functioning of the organs of the reproductive system makes itself felt by pain in the genital organs, their dryness, and a decrease in libido. Calcium is in short supply during this period, due to which the bone tissues become thinner and pains and cramps are felt in the limbs, pulling pains in the lower back, osteochondrosis may develop. The skin loses its elasticity and wrinkles form. The cardiovascular system suffers no less than others, letting you know about yourself with headaches and heart pains, jumps in blood pressure, and dizziness. Femoston with menopause helps to cope with all these symptoms.

Experts also note such a beneficial effect of Femoston at a dosage of 2/10, such as endometrial thickening. With early menopause, it helps to induce ovulation and increase the chance of pregnancy.

Composition and mechanism of action of the drug

Femoston is a combined hormonal agent of two-phase action. Its main active substances are micronized 17beta-estradiol and dydrogesterone. The action of the first is alternative to the hormone estradiol, the second - to progesterone.

The estrogen component replenishes the supply of estrogen in the female body, which allows you to restore the balance of the psycho-emotional system and stop the autonomic manifestations of menopause. In the postmenopausal phase, the substance prevents the deterioration of bone mass.

The gestagenic substance - dydrogesterone ensures the natural course of secretion in the endometrium, thereby eliminating the risk of developing neoplasms in it and preventing the development of a number of hormone-dependent diseases.

In combination, these substances help to effectively eliminate the symptoms of menopause, stabilize metabolism, lower cholesterol levels, prevent possible diseases and tumors of various kinds, and even rejuvenate the body to some extent, both inside and out.

Experts note that estradiol, entering the body, is easily absorbed and metabolized mainly in the liver. Excreted with urine.

Dydrogesterone is also rapidly absorbed, completely metabolized and excreted in the urine after 72 hours.

Excipients are corn starch, colloidal silicon dioxide, lactose monohydrate, hypromellose, magnesium stearate.

Forms of release and methods of application of Femoston

As already noted, there is a line of this medication from such funds: Femoston 1/10, Femoston 2/10 and Femoston 1⁄5 conti. The first number means the amount in mg of estradiol in 1 tablet, the second - didrogesterone. Tablets have a shell of a certain color for each type of medicine. They are round and convex on both sides.

How to take the drug and its correct dosage can only be determined by a specialist, having previously carried out a complete diagnosis and excluded all contraindications.

The instruction prescribes to take Femoston according to the following system:

• The dosage of Femoston is 1/10. Enough once a day, 1 tablet at the same time orally. It does not depend on food intake. The first 14 days are used white tablets, from the 15th to the 28th day - gray.
• 1⁄5 conti. 1 time per day at the same time, regardless of the meal. If the medication was missed, then it must be consumed no later than 12 hours. It is not recommended to drink an additional pill, as this can provoke.
• Femoston 2/10 take one piece a day at a certain time. The first 14 days, pink tablets are used, from the 15th day - light yellow.

Contraindications and side effects of the drug

Since this medicine is hormonal, it has a wide range of contraindications, which include:

• Individual intolerance to any component.
• Pregnancy and lactation.
• Breast cancer or suspicion of it.
• Estrogen-dependent neoplasms or suspicions of such.
• endometrial hyperplasia.
• Vaginal or uterine bleeding of unknown origin.
• All types of liver diseases.
• Kidney disease, renal and adrenal insufficiency.
• Porfiry.
• Thromboembolism of the veins, suspicions of it.
• Arterial thromboembolism.

With caution, this medication should be taken by diabetics, people with cardiovascular diseases.

Before using it, you need to undergo extensive diagnostics, take into account the risk of developing hereditary diseases, lifestyle.

This remedy can cause numerous side effects. For example, breakthrough bleeding, pain in the pelvis and mammary glands, as well as their increase, erosive changes in the cervix, changes in the quality of sexual life, such as vomiting, nausea, diarrhea, flatulence; headache, dizziness, chorea, thromboembolism; various kinds of allergic reactions, such as itching, rashes, redness.

While taking the drug, rejection of contact lenses, weight gain, vaginal candidiasis may be detected. If such manifestations are detected, it is urgent to contact a specialist to correct therapy and, if necessary, stop using the medication.

The drug does not affect the concentration of attention and the ability to control mechanisms.

Regarding interaction with other agents and substances, it is noted that inducers of microsomal enzymes in the liver reduce the estrogenic effect of the drug. Some herbal remedies, including herbal teas, collections and tinctures stimulate the exchange of estrogens and progestogens.

Means analogues

There are a huge number of drugs that stop menopausal symptoms. They have a different origin and form of release. Phytohormones, homeopathy, dietary supplements. As for the drugs used in hormone replacement therapy, their groups are determined depending on the hormone, the action of which they model.

In this case, according to the presence of estradiol, analogues are such means as Divina, Klimonorm, Clinorette. And also, about which they have a positive character. But according to the combination of estradiol and dydrogesterone, Femoston does not have analogues.

Opinions of doctors and patients about the drug

The drug Femoston collects quite conflicting reviews of doctors and patients. Someone talks about the effectiveness of only a representative of the line - Femoston 1⁄5 Conti at all stages of the menopause, others are generally opposed to hormone replacement therapy. Reviews on the Internet and the media speak of the effectiveness of all three tools.

At a concentration of 1 and 5 mg, respectively. As auxiliary components are used: lactose in the form of monohydrate, methyl hydroxypropyl cellulose, anhydrous colloidal silicon dioxide, corn starch, macrogol 400, magnesium stearate, iron dyes (yellow oxide E172 and red E172), titanium dioxide (E171), Opadry orange.

Tablets have the same composition. Femoston Conti 1/5.

IN tablets Femoston 1/10 white color is used as an active component estradiol . The concentration of the substance is 1 mg / tab. Each gray tablet Femoston 1/10 estradiol And dydrogesterone contained in a ratio of 1:10 (1 mg estradiol for 10 mg dydrogesterone ).

In pink tablets Femoston 2/10 contains as an active ingredient estradiol at a concentration of 2 mg / tab. In light yellow tablets estradiol And dydrogesterone contained in a ratio of 2:10 (2 mg estradiol for 10 mg dydrogesterone ). Auxiliary components: lactose in the form of monohydrate, hypromellose, magnesium stearate, corn starch, colloidal silicon dioxide, Opadry (respectively, white, gray, pink and yellow).

Release form

The dosage form of the drug is film-coated round, biconvex tablets with a diameter of 0.7 cm. The tablets differ in color depending on the concentration of the active substance / substances, each of them has the marking “379” on one side.

On tablets Femoston 1/5 the letter “S” is engraved on the other side. Tablets are available in calendar packs of 28 pieces.

Tablets with a higher concentration of active substances are packaged in calendar packages as follows:

• 14 white tablets 1 mg + 14 gray tablets 1 mg + 10 mg (Femoston 1/10);
• 14 pink tablets 2 mg + 14 light yellow tablets 2 mg + 10 mg (Femoston 2/10).

pharmachologic effect

Anticlimacteric estrogen-progestogen for “calendar” (sequential) reception.

Pharmacodynamics and pharmacokinetics

Femoston is combined hormonal drug used to eliminate symptoms of estrogen deficiency and treatment of DMK - dysfunctional uterine bleeding .

• hyperhidrosis;
• tides;
• involution of the mucous membranes and skin, and especially the mucous membranes of the urogenital tract (in particular, the vaginal mucosa, due to which the woman begins to experience discomfort during sexual intercourse);
• increased nervous excitability;
• headaches and dizziness;
• sleep disorders;
• loss of bone mass or (especially if certain risk factors are noted, long-term treatment glucocorticosteroids in the recent past, early onset menopause , asthenic body type, smoking, etc.).

Also estradiol helps to reduce concentration general and low-density LP, while simultaneously increasing the concentration of high-density LP.

Action gestagenic component of the drug dydrogesterone - is aimed at stimulating the onset of the secretory phase of the endometrial cycle, and also reduces the risk carcinogenesis And endometrial hyperplasia, associated with influence estrogen .

Dydrogesterone does not provide androgenic estrogenic , glucocorticosteroid or anabolic action . For maximum preventive effect (HRT), treatment is recommended to start as soon as possible after the onset of menopause .

After taking p / os, estradiol is easily absorbed. The biotransformation of a substance is carried out in liver , the products are estrone And estrone as sulfate . Estradiol And estrone glucuronides eliminated from the body mainly in the urine.

Dydrogesterone also rapidly absorbed from digestive tract after receiving p/os. The substance is completely biotransformable, the main product metabolism - 20-dihydrodydrogesterone. breeding metabolites carried out mainly with urine.

Half-life dydrogesterone - from 5 to 7 hours, its main metabolite - from 14 to 17 hours, the substances are completely excreted after 72 hours.

Indications for use

The use of Femoston is indicated for hormone replacement therapy to eliminate the phenomena caused estrogen deficiency in women in postmenopausal period .

The medicine is prescribed no earlier than six months after the last menstrual bleeding.

Prophylactic administration of the drug is advisable to prevent the development osteoporosis after the onset menopause . The drug is prescribed to women who have an increased risk of fractures and who are contraindicated in the use of other drugs intended to prevent bone loss.

Contraindications

The drug is not prescribed:

• women who have been diagnosed in the past malignant estrogen- or progestogen-dependent tumors , as well as if there are suspicions of these diseases;
• patients diagnosed or suspected;
• at vaginal bleeding unspecified nature of origin;
• at untreated hyperplasia (pathological growth) endometrium ;
• with a currently detected or noted in the anamnesis venous thromboembolism (including but not limited to DVT and PE);
• if the patient has some thrombophilic disorders (including when thrombophilia associated with deficiency antithrombin , coagulation protein C or its cofactor protein S );
• at thromboembolic diseases of the arteries , including including or (both in the active stage and in cases where the disease has been transferred in the recent past);
• with active disease liver , and also, if the patient has not recovered after the illness biochemical parameters of the liver ;
• at porphyrin disease ;
• if known about individual intolerance estradiol , dydrogesterone or auxiliary components of Femoston;
• children and adolescents under 18;
• during pregnancy (both established and if pregnancy is suspected);
• during lactation.

Side effects

The category of side effects that often occur in connection with the use of Femoston include: pain (headaches, in the abdomen, in the pelvic area), nausea, migraine attacks, flatulence, leg cramps, increased sensitivity and / or soreness of the mammary glands, metrorrhagia, the appearance of bloody vaginal bleeding after the onset of menopause, asthenia, weight loss/increase.

With a frequency of 1/1000-1/100 in the course of clinical studies, phenomena such as:

• vaginal candidiasis ;
• depression;
• size increase uterine fibroids ;
• change libido ;
• increased nervousness;
• DVT, PE;
• dizziness;
• disease gallbladder ;
• backache;
• allergic reactions on the skin, accompanied by itching, rashes;
• ulcers on the cervix ;
• the appearance of cervical discharge;
• peripheral edema.

In rare cases (with a frequency of 1/10000-1/1000), drug therapy was accompanied by:

• intolerance to contact lenses;
• functional disorders liver , which often appear as asthenia , malaise, abdominal pain, jaundice ;
• an increase in the curvature of the cornea of ​​\u200b\u200bthe eye;
• enlargement of the mammary glands;
• premenstrual tension syndrome.

In isolated cases, the drug can provoke the development chorea , hemolytic anemia, stroke, myocardial infarction, vascular purpura, vomiting, erythema nodosum or polymorphism, melanopathy, or chloasma(often persisting even after discontinuation of the drug), angioedema , hypersensitivity reactions, worsening porphyrin disease .

In addition, in connection with the treatment estrogen-progestogen drugs women sometimes develop neoplasms (benign, malignant or unknown etiology), increase in size progestogen-dependent tumors , appear fibrocystic lesions of the mammary glands , the concentration increases triglycerides in and concentration thyroid hormones ; develop arterial hypertension , acute blockage arteries , peripheral vascular disease, (against the background of pre-existing hypertriglyceridermia), cystitis-like syndrome , urinary incontinence; aggravated, symptoms appear.

Femoston tablets: instructions for use

Most often, Femoston is taken on days strictly defined by the attending physician, taking into account the characteristics of a particular menstrual cycle . In the absence of menstrual bleeding, the tablets should be taken on the expected days when they should have started. At amenorrhea observed during the year, the drug can be started at any time.

Instructions for use Femoston 1/5

The drug is intended for continuous use: tablets are taken p / os, one per day (optimally - at the same time), without being tied to the time of eating. The duration of one cycle is 4 full weeks (1 package No. 28 is designed for one cycle). There is no need to take a break between cycles.

For relief of symptoms menopause the drug is started with the minimum effective dose. Treatment begins with the appointment of Femoston 1/5. Considering the timing menopause, the severity of the symptoms accompanying it and the effectiveness of therapy in the dosing regimen may be adjusted.

If necessary, the transition from another having in its composition estrogen And progestogenic components of the drug for sequential (or cyclic) administration, the patient should complete a full four-week course and only after that proceed to treatment with Femoston 1/5 (reception can be started on any day). There is no break between cycles.

The scheme of application of the drug Femoston 1/5 Conti is similar to that described above.

Instructions for use Femoston 1/10

Femoston 1/10 tablets should be drunk regardless of the meal time. Estrogen as part of the drug is intended for continuous daily intake during the first two weeks of the cycle.

Progestogenic the component is added in the last 14 days of each four-week course.

Treatment begins with taking white tablets according to the scheme: 1 tablet 1 time per day (at the same time) during the first 2 weeks of the cycle. Further, following the instructions on the package, they begin to take gray tablets (also, one per day).

There is no need to take breaks between 28-day cycles.

Sequential combined HRT begins with the appointment of Femoston 1/10, in the future, if necessary, the dose is adjusted taking into account the clinical results of therapy.

To switch from a similar drug, you should complete the full cycle of treatment and only then start taking Femoston 1/10 tablets. You can do this on any day.

Instructions for use Femoston 2/10

estrogen component of the drug should be taken continuously, progestogenic the component is administered from the 15th day of the 28-day cycle.

This means that in the first 2 weeks of the cycle, the patient should take 1 pink tablet per day, and, starting from the 15th day, following the instructions on the drug package, switch to taking yellow tablets.

Usually starting dose estradiol - 1 mg, therefore, sequential combined HRT is started with Femoston 1/10 and, if necessary, they eventually switch to a higher dose.

The transition from other drugs to Femoston 2/10 is carried out only at the end of a full four-week cycle (on any day).

How to take Femoston in case of missing the next dose?

If a woman misses the next dose of the drug, the pill should be taken as soon as possible. If more than 12 hours have passed after the pass, then the course is continued by taking the next tablet from the package (you do not need to drink the missed one).

Taking a double dose to make up for a missed dose is not advisable, as it is associated with an increased risk of breakthrough bleeding and the appearance of spotting vaginal discharge.

How to take the drug to patients of different age groups?

There is no sufficient experience in the use of Femoston for the treatment of patients over 65 years of age.

There are no indications for prescribing the drug to children and adolescents.

Overdose

Cases of overdose with Femoston have not been recorded.

AND estrogenic , And progestogenic the components of the tablets are classified as low-toxic substances.

Theoretically, an overdose can provoke an increase in the severity of such side effects as: nausea, vomiting, dizziness, drowsiness.

It is unlikely that any specific symptomatic treatment may be required due to an overdose (including overdose in children).

Interaction

Femoston drug interaction studies have not been conducted.

However, it is known that some drugs may affect the effectiveness estrogen And progesterone .

For example, anticonvulsants (eg. phenytoin or ) and antimicrobial (including nevirapine , or efavirenz ) drugs enhance the biotransformation of these substances, which is associated with their ability to induce those involved in metabolism medicinal product enzymes of the cytochrome P450 system .

Ritonavir And nelvinavir , which are potent inhibitors of CYP isoenzymes 3A4, A5 and A7, in combination with steroid hormones , contribute to the activation of these cytochromes.

Phytopreparations , which are based on St. John's wort (Hypericum) perforatum, can stimulate biotransformation estrogen And progestogens due to the ability to act on the CYP 3A4 isoenzyme.

There is evidence that more actively flowing estrogen metabolism And progestogens provokes a decrease in the clinical effectiveness of these substances and affects the profile of uterine bleeding.

In its turn estrogens can disrupt the process of biotransformation of other substances due to competitive suppression cytochromes of the P450 system , which take part in the processes of biotransformation of the active substances of drugs.

This should be kept in mind when assigning estrogens in combination with drugs with a narrow therapeutic index, including fentanyl , , theophylline , cyclosporine .

Such combinations can cause an increase in the plasma concentration of these substances to a toxic level. Therefore, it may be necessary to carefully monitor the drug over an extended period of time, as well as dose reduction. cyclosporine, tacrolimus, theophylline and fentanyl .

Terms of sale

On prescription.

Storage conditions

The optimal storage conditions for Femoston tablets are to maintain a temperature of no more than 30 degrees Celsius. The drug must be stored in its original packaging. Keep away from children.

Best before date

The drug is suitable for use within 36 months after the date of issue.

special instructions

The drug is recommended to be used only in the presence of symptoms that have an adverse effect on the quality of life. Treatment is continued until the benefit of using the drug outweighs the risk of side effects.

Analogues

Coincidence in the ATX code of the 4th level:

The generic (structural analogue) of Femoston ⅕ is Femoston Conti 1/5.

Drugs with a similar mechanism of action:,.

Klimonorm or Femoston - which is better?

Deciding which drug from the combination group estrogen-progestin drugs you should choose whether the doctor takes it based on the data received from the patient about the period of age-related hormonal changes.

It is believed that the drug Klimonorm gestagenic the component is present in the most optimal concentration, which allows you to effectively control the cycle and provides the necessary level protection of the endometrium from the hyperplastic effect of estrogen .

At the same time, it is possible to maintain favorable effects due to the influence of estrogen on the state cardiovascular system and lipid metabolism . In addition, contained in Klimonorme potentiates action estradiol for the treatment and prevention osteoporosis .

Another important feature levonorgestrel is its almost 100% bioavailability, thanks to which it is possible to maintain the stability of the effects of the drug.

Moreover, the severity of the effects remains unchanged regardless of the woman’s diet, whether she has digestive tract diseases , as well as activities hepatic system , which plays a key role in the processes first pass metabolism of xenobiotics .

Bioavailability dydrogesterone , which is part of Femoston, is 28%, and therefore its effects are subject to fluctuations (both inter- and inter-individual).

Angelique or Femoston - which is better?

Experts believe that there is no particular difference between these funds. The main difference between the drug and Femoston is that, as gestagenic component it includes at a concentration of 2 mg / tab.

Use with alcohol

In the manufacturer's instructions, the interaction of Femoston with alcohol is not described.

During pregnancy

The use of Femoston is contraindicated if it is known for sure that the woman is pregnant, and also, if there is reason to assume pregnancy. It is also contraindicated to take the drug for women who are breastfeeding.

In some cases, the drug is prescribed during pregnancy planning. The indications are:

• deficiency conditions. estrogen and manifested by insufficiency of the first phase (that is, conditions in which, by the end of the first (follicular) phase menstrual cycle the thickness of the endometrial layer does not exceed 7-8 mm);
• infertility caused by hormonal imbalance.

Too thin endometrium can cause a violation of the luteal phase and, as a result, the fact that a woman cannot become pregnant.

Concentration estradiol in tablets intended for use during the first 2 weeks of the cycle, such that the drug, unlike contraceptives, does not suppress ovulation , while modeling the first phase menstrual cycle and stimulates cell division and growth.

Taking pills containing estradiol added dydrogesterone, in turn, provides secretory transformation inner layer of the uterus necessary for normal implantation eggs in case of fertilization and pregnancy. Thus, Femoston 2/10 allows you to normalize the disturbed menstrual cycle .

Femoston 2/10 when planning pregnancy is taken from the first day of the menstrual cycle, one tablet per day for 4 full weeks. Do not stop treatment before the entire package is finished, as this can provoke a hormonal imbalance, manifested by breakthrough bleeding of varying degrees of intensity and leaving no chance of pregnancy.

Women who, when planning pregnancy, take Femoston should further strengthen the luteal (second) phase of the cycle, therefore, from the 14th day of treatment, the patient is prescribed to take the drug in combination with (or its equivalent).

As gestagenic component in Duphastone present dydrogesterone , and this allows you to enhance the positive effect of therapy on the female body and condition endometrium .

Duphaston take one tablet twice a day for a full two weeks.

Can I get pregnant while taking the drug?

Pregnancy that occurred during the period of Femoston use is an exception. As a rule, the chances of getting pregnant after taking the drug for several cycles are considered more realistic, and this usually occurs after stopping treatment.

In extremely rare cases, it is possible to use the remedy against the background of an already completed pregnancy, when a woman needs support endometrium . However, such a decision can only be made by a qualified specialist.

Reviews about Femoston

A considerable number of reviews about Femoston 1/5 Conti have been left on the forums. Like reviews of Femoston 2/10 or 1/10, they are quite contradictory. As a rule, in the reviews, women describe the experience of using the remedy for menopause or when planning pregnancy .

Those who were satisfied with the treatment, as the advantages of the drug, note that it is quite well tolerated and rarely causes side effects, quickly normalizes the condition, stopping the unpleasant symptoms of the onset menopause , and improves overall well-being, has a positive effect on the condition of the skin, restores the cycle in case of violation, and is convenient to use.

Negative reviews are associated with the occurrence of unwanted side effects (depression, rash, excess weight, edema, decreased activity, joint pain, etc.), as well as the lack of the expected effect.

Referring to the doctors' reviews of Femoston 1/10, 2/10 or 1/5, which are based on the results of clinical studies, we can conclude that the drug is a highly effective tool for the treatment and prevention of conditions that have developed due to premature exhaustion ovaries .

At the same time, all patients showed good tolerability of the tablets. Studies have established a pronounced positive effect of therapy on the general well-being of women and, in particular, on blood lipid profile .

Against the background of the treatment, a significant increase in the indicator of maximum oxygen consumption and an increase in dydrogesterone bone-protective estrogen Femoston component.

Thus, doctors confirm the need for early initiation and differentiated choice of hormone replacement therapy in women with "off" ovarian function .

Femoston price

Price Femoston 1/5 in Russian pharmacies from 870 rubles. Buy Femoston Conti 1/5 can be an average of 900 rubles. Price Femoston 2/10— from 790, Femoston 1/10- from 795 rubles.

Currently, obstetricians and gynecologists often prescribe the drug Femoston for menopause. Reviews of doctors are diametrically opposed, but in the vast majority of cases positive. Let's figure out what this drug is.

The composition of the medicinal product

The main active ingredients are estradiol and dydrogesterone. Some of the tablets contain only estradiol (1 or 2 mg - depending on the drug), and the second half of the tablets also contain 10 mg of dydrogesterone. And, of course, a variety of excipients that are part of the shell of the tablets.

When appointed

The indication for the appointment of this drug is estrogen deficiency in women. It is used no earlier than 6 months after the last menstruation. Climacteric manifestations in each patient may be individual, but general symptoms are still present. These are hot flashes, irritability, dry skin and mucous membranes (including the vagina), pain during intercourse, and unstable blood pressure.

Another indication is the prevention of osteoporosis in postmenopausal women. In this situation, the drug is prescribed even in the absence of clinical manifestations of menopause, if there are contraindications for the use of specialized drugs for the treatment of osteoporosis.

Have you prescribed the medicine "Femoston"? Reviews for menopause will be positive if the drug is suitable for the patient, and she tolerates it well. Otherwise, you may need to select another drug.

How to apply

The package contains 28 tablets. All of them contain estrogen for continuous use. The second 14 tablets also added progesterone. Therapy begins with taking pink tablets, and then they switch to yellow tablets. The drug is used without interruption: after the end of the package, the next one immediately begins.

Preparations for menopause: "Femoston" 2/10, 1/10, 1/5 conti - are prescribed in different situations. A dosage of 1/5 conti is used in women with a long-term menopause, when there are no pronounced menopausal symptoms, but the drug is needed to prevent bone fractures associated with the development of osteoporosis, to stabilize the course of hypertension, when taking antihypertensive drugs alone does not give the desired effect. In this situation, when prescribing the drug, doctors about it are only positive. This is especially true for cardiologists who are not afraid to recommend A to their patients as a result of a stable decrease in blood pressure and a decrease in the risk of developing acute myocardial infarction.

The instructions for the drug state that the experience of use in women over 65 years of age is limited, but this does not mean that it is impossible. The main thing is to correctly weigh all the pros and cons.

Alternative uses

The drug "Femoston" 2/10, reviews of which can be found on most women's sites, is currently also used in patients of reproductive age. The question arises: "What for?" After all, this indication is not spelled out in the instructions. Nevertheless, reproductologists have found that due to the fact that the composition of the drug is identical to natural, it helps well to cope with such a problem as thin endometrium. These are situations when the mucous membrane of the uterine cavity does not correspond to the day of the menstrual cycle, which leads to the impossibility of developing a pregnancy even if the egg is fertilized.

But what does practice show, does pregnancy occur on Femoston 2/10? The reviews on the forums are mostly negative. Patients complain that the menstrual cycle goes astray, the discharge itself becomes abundant, and there was no ovulation, and there is still no endometrium in someone. But there are also isolated positive reviews. This suggests that the drug, in combination with the addition of duphaston in the second phase of the cycle, has a positive effect, pregnancy occurs, only the course of treatment should not be 2-3 months, but at least six months. Therefore, the drug "Femoston" 2/10, reviews of which can be found, are diametrically opposed.

The drug "Femoston" 1/10, reviews of which are also easy to find, has more positive recommendations. Some doctors are trying to prescribe it to patients of reproductive age in order to regulate the menstrual cycle. But here, as a rule, it does not work - an insufficient level of hormones. And when prescribed to women of menopausal age, it works well. "Femoston" 1/10 patient reviews are mostly positive. It is well tolerated with virtually no side effects.

Summing up, we can say that the drug "Femoston", the reviews of doctors confirm this, is the safest and most effective in the treatment of manifestations of menopausal syndrome, normalization of the menstrual cycle and preparation for pregnancy in women with

For children and adolescents, this drug is not used.

Negative manifestations

Like any medicine, this drug can have side effects. It depends on their severity whether the patient will continue to use the drug in the future. These manifestations include:

• headaches, may be migraine-like pain;
• dyspeptic phenomena;
• pain in the abdomen;
• flatulence of the intestine;
• leg cramps;
• soreness of the mammary glands;
• violation of the menstrual cycle, which can be manifested by profuse discharge, pain syndrome, spotting spotting in the middle of the cycle;
• fluctuations in weight (someone notes its decrease, and someone, on the contrary, an increase in body weight).

Of the rare manifestations, it is worth noting: the development of candidiasis, an increase in a decrease in sexual desire, mood swings, syncope, the development of thrombosis, the formation of gallbladder stones, allergic manifestations to the components of the drug, edema, due to which weight may increase.

But, despite all this, you can safely take Femoston. Reviews of doctors show that the drug is well tolerated, side effects are rare or mild.

When the drug should not be used

This medicinal product must not be used for:

• hypersensitivity to any component of the drug;
• breast cancer in the past or present;
• the presence of hormone-dependent formations;
• bleeding from the genital tract for an unexplained reason;
• endometrial hyperplasia in the absence of a histological conclusion;
• thrombosis in the past or present;
• thrombophilia;
• IHD, acute myocardial infarction, ischemic stroke;
• exacerbation of liver disease;
• porphyria;
• pregnancy and lactation;
• patients under the age of 18 years.

In gynecological practice, the drug "Femoston" is often prescribed for menopause. Reviews of doctors make it possible to track the frequency of occurrence of certain side effects, help to find ways to deal with them.

Issue price

The price of the drug may vary depending on the region and on the pharmacy chain. But in general, the cost of the medicine ranges from 499 rubles per pack to 1310 rubles. The dosage of the drug "Femoston" also plays a role here. Price, reviews are available on the official website of the manufacturer.

Results

When using the drug "Femoston" with menopause, the doctors' reviews claim that the patient receives an improvement in well-being due to the cessation or significant reduction of menopausal symptoms, prevention of the development of osteoporosis (and with it the prevention of bone fractures), protection from the progression of cardiovascular pathology.

Every woman at any age wants to look healthy and attractive. Hormone replacement therapy helps to fulfill this desire. Should I use the drug "Femoston" for menopause? Doctors' opinions say yes.

• Date: 30-04-2019
• Views: 344
• Comments:
• Rating: 0

The combined medical preparation Femoston 2/10 is prescribed during hormone replacement therapy. It contains analogues of hormones produced in the body of a girl or woman - estradiol with progesterone. The first is able to replace micronized 17-beta-estradiol, and the second - dydrogesterone. This tool is considered quite effective, however, it also has side effects.

The main characteristics of the tool

Estradiol is easily absorbed. This component is well metabolized. This process is entirely carried out in the liver. Estrone and estrone sulfate are formed. Estradiol and estrone glucuronides are excreted from the body through the genitourinary system.

Dydrogesterone is absorbed from the gastrointestinal tract. The main metabolite is 20-dihydrodydrogesterone. Its presence in the urine as a conjugate of glucuronic acid is noted. Dydrogesterone is completely eliminated from the body 72 hours after taking the medicine. The indication for taking Femoston is replacement therapy for disorders that appear in the body due to menopause.

Femoston 2/10 is prescribed every day for 1 tablet. You can't miss. The first 2 weeks of the cycle, consisting of 28 days, the patients drink orange tablets, each containing 2 mg of estradiol. The next 2 weeks, women take yellow pills. They consist of 2 mg of estradiol and 10 mg of dydrogesterone.

In the presence of menstruation, Femoston 2/10 is taken on the first day of the monthly cycle. When menstruation is not regular, the medication should be switched to after gestagen monotherapy for 10-14 days. If menstruation has disappeared for more than 12 months, the patient can start taking Femoston 2/10 whenever she wants.

ARVE Error:

The drug is available in the following dosage:

• Femoston 1/5 Conti, which contains 1 mg of estradiol and 5 mg of dydrogesterone;
• Femoston 1/10, which includes 1 mg of estradiol and 10 mg of dydrogesterone;
• Femoston 2/10 containing estradiol - 2 mg, dydrogesterone - 10 mg.

The effectiveness of the course of therapy

Instructions for use of the medicinal product must be strictly observed. The dosage of the drug can be different, and only a specialist can determine it correctly. Self-medication with hormonal drugs can disable the vital systems of the body. It is recommended to collect an anamnesis before starting a course of hormone replacement therapy: medical and family.

A woman should be examined to determine if she has contraindications. Conditions are often observed when treatment with the drug is possible, but all precautions must be taken. A patient taking Femoston 2/10 should be constantly monitored by a doctor. During the course of hormonal therapy, it is necessary to conduct regular examinations, which allows you to assign an individual frequency of use of the drug.

Get a mammogram to examine your breasts. Estrogens interfere with liver and thyroid tests. They change the analysis for sugar with a load. The risk of thrombosis appears with excess body weight.

When prolonged immobilization is required after surgery, then it is advisable not to take Femoston 2/10 before surgery for 4 or 5 weeks.

ARVE Error: id and provider shortcodes attributes are mandatory for old shortcodes. It is recommended to switch to new shortcodes that need only url

If a patient has recurrent deep vein thrombosis and is being treated with anticoagulants, then the likely risks will need to be assessed. When, after the start of a course of replacement therapy, thrombosis develops in patients, it must be canceled. Women should contact their doctor as soon as the following symptoms appear:

• swelling of the legs;
• loss of consciousness;
• the appearance of vision problems;
• dyspnea.

If the patient has previously been treated with estrogenic drugs, then she needs a particularly thorough examination before HRT. In the process of conducting the study, the doctor will be able to identify the problem of endometrial hyperstimulation. Femoston 2/10 in the first months of admission causes hormonal changes in the body. A woman may experience bleeding: uterine and menstrual-like. In this case, dose adjustment is necessary. If the bleeding does not stop, Femoston 2/10 is canceled. It is important to find out the reason for its appearance.

Contraindications for admission

There are contraindications to the use of Femoston. In each case, you have to understand carefully in order to make the right decision. The negative effects of taking a drug can seriously harm human health. If the patient has endometrial or breast cancer, Femoston 2/10 cannot be prescribed. Any hormone-dependent neoplasms can begin to progress. Particular attention should be paid to endometrial hyperplasia.

In liver diseases, the drug in most cases is not used in replacement therapy. Deviations from the norm, as a rule, can provoke severe complications and cause a worsening of the patient's condition. Acute venous thromboembolic disorders are contraindications for taking Femoston.

If the patient has genital bleeding, the etiology of which is unknown, the course of the drug may not be appropriate. The drug should not be taken by pregnant women. Caution must be observed in renal failure. When the body has hypersensitivity, then it can react to any component of the drug. In addition to analogues of hormones, the composition includes additional substances:

• lactose monohydrate;
• silicon dioxide colloidal;
• hypromellose;
• magnesium stearate;
• corn starch;
• Opadry OY-6957 and OY-02B22764.

It is not recommended to take Femoston when the patient's condition worsened after she took the pill. An alarming sign is a feeling of soreness in the mammary glands. Be sure to consult with your doctor, who will be able to choose a more suitable drug. A woman is not prescribed such a medication during lactation.

It is undesirable for serious violations of cerebral circulation. The patient must know how to take the pills. Incorrect dosage of the medicine is unacceptable. Taking two pills a day instead of one can lead to serious consequences. In case of an overdose, drowsiness, nausea, vomiting, dizziness appear.

Treatment is carried out with the help of symptomatic therapy. At the same time, it is important to take the necessary measures in a timely manner. Be careful, get yourself a calendar where you will mark the days of taking the medication. The instructions for use will remind you of the dosage in case you lose your doctor's prescription.

ARVE Error: id and provider shortcodes attributes are mandatory for old shortcodes. It is recommended to switch to new shortcodes that need only url

The conducted studies have confirmed that with the regular use of Femoston, a woman does not experience any disturbances in the functioning of the motor apparatus. The patient may be physically active. She is able to manage complex mechanisms or drive a vehicle.

Drug interactions and effective analogues

The simultaneous use of various medications can slow down the healing process. Femoston 2/10 is not recommended when the patient is treating the liver with microsomal enzyme inducers. These include barbiturates, rifampicin, phenytoin, etc. When interacting with the listed agents, the estrogenic effect of Femoston becomes weaker.

Nelfinavir or Ritonavir will be inducers, although they are inhibitors of microsomal metabolism. Herbal preparations, which contain St. John's wort, stimulate the exchange of estrogens. If we consider how dydrogesterone interacts with other medicines, nothing is known about this at the moment.

It is impossible to find an analogue of Femoston in structure: the active substance is used only in this preparation. To some extent, the following agents are able to replace the medication for the therapeutic effect:

• Angelique;
• Ginodian Depot;
• Artemis;
• Duphaston;
• Inoklim and others.

The above medications do not have the versatility of Femoston. Estradiol is able to completely compensate for the lack of estrogen in a woman's body. As a result, during menopause, a woman is practically not bothered by menopausal symptoms, including hot flashes, insomnia, increased sweating, and dryness of the vaginal mucosa. She tolerates age changes more easily.

Dydrogesterone is a progestogen. In the endometrium, it is he who provides the secretion phase. Its reception reduces the development of hyperplasia. Dydrogesterone does not show estrogenic, androgenic, anabolic and glucocorticosteroid activity. When a woman cannot become pregnant due to a thin endometrium, Femoston effectively helps. The drug helps to normalize the level of female sex hormones. As a result, the endometrium begins to develop correctly.

ARVE Error: id and provider shortcodes attributes are mandatory for old shortcodes. It is recommended to switch to new shortcodes that need only url

Side effects

If the patient was prescribed Femoston, she needs to be more attentive to her condition so as not to miss the side effects. There are blisters in a cardboard box, 1, 3 or 10, instructions. On the part of the reproductive system, the following manifestations can be observed: soreness of the mammary glands, changes in libido, genital candidiasis, pain in the lower abdomen, discharge with blood from the genitals.

The digestive system may also respond to the action of a hormonal drug with undesirable manifestations. The patient may experience nausea, abdominal pain. Vomiting with flatulence and cholestatic jaundice indicates the presence of side effects.

If Femoston is not suitable, then there will be problems with the central nervous system. The patient will suffer from headaches, dizziness, depression, migraine and chorea. A woman constantly experiences a feeling of nervous tension. Her nervousness annoys everyone around her.

Skin reactions appear as a rash. The patient constantly feels severe itching. A woman may develop hemorrhagic purpura, chloasma, melasma, porphyria, or erythema, nodular and multiform.

On the part of the cardiovascular system, an increase in blood pressure can be expected. One of the most dangerous side effects are thrombosis with thromboembolism. Among the negative effects of hemolytic anemia. With serious violations of the functioning of the cardiovascular system, taking Femoston may result in myocardial infarction.

It is possible to prevent undesirable consequences. The patient should tell the attending physician what diseases she has and what treatment she is receiving. This will help not to make a mistake when prescribing the drug and to choose the right dosage.

ARVE Error: id and provider shortcodes attributes are mandatory for old shortcodes. It is recommended to switch to new shortcodes that need only url

It is impossible to remain silent about the presence of serious diseases: the effect of hormonal drugs is so strong that it can lead to failures in the normal functioning of the human body.

Take your health seriously. Femoston may cause weight changes. Some patients begin to suffer intolerance to contact lenses. The calf muscles are convulsing. Women have periodic edema.